ArTS Archivio della ricerca di Trieste

GENERALI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.802
EU - Europa 11.007
AS - Asia 6.456
SA - Sud America 1.053
AF - Africa 162
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 6
Totale 38.511
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.656
PL - Polonia 4.669
SG - Singapore 2.189
CN - Cina 1.751
IT - Italia 1.514
HK - Hong Kong 1.252
SE - Svezia 1.140
BR - Brasile 904
DE - Germania 657
RU - Federazione Russa 465
UA - Ucraina 454
NL - Olanda 431
TR - Turchia 340
FI - Finlandia 310
VN - Vietnam 305
IE - Irlanda 267
BG - Bulgaria 262
GB - Regno Unito 242
FR - Francia 219
KR - Corea 131
IN - India 119
ES - Italia 85
CA - Canada 70
AT - Austria 69
MA - Marocco 67
AR - Argentina 61
BE - Belgio 53
MX - Messico 49
JP - Giappone 44
MY - Malesia 39
RO - Romania 31
ZA - Sudafrica 31
BD - Bangladesh 29
IL - Israele 28
IQ - Iraq 25
IR - Iran 24
EC - Ecuador 23
AU - Australia 22
PK - Pakistan 22
CH - Svizzera 21
ID - Indonesia 19
SA - Arabia Saudita 17
CZ - Repubblica Ceca 16
CL - Cile 15
SN - Senegal 15
PY - Paraguay 14
TH - Thailandia 14
AE - Emirati Arabi Uniti 13
CO - Colombia 13
EE - Estonia 12
LT - Lituania 12
TW - Taiwan 11
EG - Egitto 10
JO - Giordania 10
AM - Armenia 9
DK - Danimarca 9
KE - Kenya 9
OM - Oman 9
TN - Tunisia 9
DZ - Algeria 8
GR - Grecia 8
HU - Ungheria 7
MD - Moldavia 7
NO - Norvegia 7
RS - Serbia 7
UZ - Uzbekistan 7
VE - Venezuela 7
AZ - Azerbaigian 6
CR - Costa Rica 6
HR - Croazia 6
PE - Perù 6
PH - Filippine 6
PT - Portogallo 6
HN - Honduras 5
MT - Malta 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BO - Bolivia 4
CI - Costa d'Avorio 4
GE - Georgia 4
JM - Giamaica 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
SC - Seychelles 4
UY - Uruguay 4
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
YE - Yemen 3
BH - Bahrain 2
BN - Brunei Darussalam 2
BS - Bahamas 2
BY - Bielorussia 2
CY - Cipro 2
ET - Etiopia 2
GY - Guiana 2
KW - Kuwait 2
LU - Lussemburgo 2
Totale 38.485
Salva come PNG Salva come JPEG
Città #
Warsaw 4.634
Fairfield 2.614
Woodbridge 1.992
Ashburn 1.872
Houston 1.627
Ann Arbor 1.351
Hong Kong 1.236
Singapore 1.166
Chandler 1.115
Wilmington 1.101
Seattle 1.084
Cambridge 955
Jacksonville 602
Trieste 478
Princeton 472
Boardman 454
Beijing 438
Hefei 391
Santa Clara 328
Izmir 309
Columbus 308
Dallas 297
Amsterdam 268
Dublin 267
Sofia 259
Moscow 221
Los Angeles 147
San Diego 128
Seoul 120
Dong Ket 108
Munich 97
Buffalo 86
London 82
São Paulo 82
Frankfurt am Main 80
Milan 80
Ho Chi Minh City 72
Helsinki 71
New York 71
Dearborn 68
Falls Church 64
Nuremberg 56
The Dalles 55
Phoenix 53
Bremen 51
Chicago 50
Redondo Beach 50
Casablanca 48
Düsseldorf 47
Brussels 44
Rome 44
Turku 44
Lappeenranta 42
Hanoi 41
Redwood City 39
Vienna 39
Norwalk 38
Dongguan 37
San Francisco 35
Kerken 34
Tokyo 33
Rio de Janeiro 31
Brasília 30
Duino-Aurisina 30
Shanghai 29
Boston 28
Guangzhou 27
Redmond 26
Toronto 25
Nanjing 24
Venice 24
Barcelona 22
Brooklyn 22
Fremont 22
Des Moines 21
Jinan 20
Belo Horizonte 19
Denver 19
Portsmouth 19
Tel Aviv 19
Atlanta 18
Hangzhou 18
Lauterbourg 18
Madrid 18
Udine 18
Johannesburg 17
Kunming 17
Padova 17
Pignone 17
San Antonio 17
Mumbai 16
Roubaix 16
Stockholm 16
Dakar 15
Poplar 15
Tappahannock 15
Tianjin 15
Zhengzhou 15
Chennai 14
Florence 14
Totale 28.858
Salva come PNG Salva come JPEG
Nome #
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 419
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 390
Advances in systemic therapy for metastatic breast cancer: future perspectives 371
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 365
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 360
NEODUCTGENESIS AS A PROGNOSTIC MARKER IN “DUCTAL” CARCINOMA IN SITU OF THE BREAST 349
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 346
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 342
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 339
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 335
Current challenges in HER2-positive breast cancer 334
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 326
Designing a broad-spectrum integrative approach for cancer prevention and treatment 325
Isolated testicular metastasis from prostate cancer 325
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 324
Bevacizumab in small cell lung cancer 322
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 310
Characterization of MTAP gene expression in breast cancer patients and cell lines 309
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 309
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 301
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 295
Broad targeting of angiogenesis for cancer prevention and therapy 293
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? 293
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 288
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study 286
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes 286
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts 277
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 276
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 258
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit 254
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 252
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 251
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 251
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 242
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. 238
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer 237
Inhibitors of Tumor Angiogenesis 236
Advances in systemic therapy for malignant mesothelioma: Future perspectives 231
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers 225
The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact 225
Apatinib for the treatment of gastric cancer 218
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis 214
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 210
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 208
PROGNOSTIC ROLE OF TUMOR INFILTRATING LYMPHOCITES (TILS) IN EPITHELIOID PLEURAL MESOTHELIOMA 206
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 205
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 205
Lenvatinib for the treatment of renal cell carcinoma 205
CDK4/6 inhibitors in HER2-positive breast cancer 197
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 192
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 191
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR 189
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 182
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 181
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 180
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 179
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 177
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 176
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 171
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 170
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data 170
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 169
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste 166
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 164
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 164
High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer 163
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 162
Ibrutinib: from bench side to clinical implications 162
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 162
RNA disruption and drug response in breast cancer primary systemic therapy 159
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 157
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 156
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights 153
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer 151
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 151
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis 151
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 151
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 149
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy 149
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? 149
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 146
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer 144
Gene expression profiling in breast cancer: A clinical perspective 144
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients 144
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 144
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 143
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 142
Granular cell tumor of the breast: a multidisciplinary challenge 142
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 140
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 139
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 139
New omics information for clinical trial utility in the primary setting 138
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 138
null 137
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) 137
Familial aggregation of gastric cancer with microsatellite instability** 137
Positron emission tomography and neoadjuvant therapy of breast cancer 137
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis 136
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 136
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010) 136
Totale 21.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.779
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.890 0 0 0 0 564 389 440 352 255 349 184 357
2021/20222.804 163 409 197 173 39 197 134 107 380 380 172 453
2022/20233.528 335 361 295 433 368 653 54 313 427 39 178 72
2023/20242.825 120 364 163 188 162 226 476 594 24 122 217 169
2024/20256.728 96 524 834 424 589 943 274 378 769 750 548 599
2025/20264.129 1.205 866 879 1.002 177 0 0 0 0 0 0 0
Totale 39.536